Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	13,604	13,687	12,581	11,808	15,791	7,940
Other Revenue	643.4	515	536.1	365.1	281.2	557
Revenue	14,248	14,202	13,117	12,173	16,072	8,497
Revenue Growth (YoY)	2.89%	8.27%	7.76%	-24.26%	89.14%	29.58%
Cost of Revenue	7,718	7,103	6,255	5,153	5,298	3,767
Gross Profit	6,530	7,100	6,862	7,020	10,774	4,730
Selling, General & Admin	2,717	2,954	2,631	2,116	1,825	1,346
Other Operating Expenses	-10	-	-2.1	-89.9	-45.6	-280.4
Operating Expenses	2,707	2,954	2,629	2,026	1,779	1,066
Operating Income	3,823	4,145	4,233	4,994	8,995	3,665
Interest Expense	-42.1	-55.2	-73	-59.4	-57.3	-56.9
Interest & Investment Income	706.6	711.4	495.9	160.1	45.8	75.4
Currency Exchange Gain (Loss)	-0.5	-0.5	-12.9	50.2	0.4	-
Other Non Operating Income (Expenses)	38.8	15.8	-20	8.8	4	19.3
EBT Excluding Unusual Items	4,526	4,817	4,623	5,154	8,988	3,702
Gain (Loss) on Sale of Investments	754.1	117.7	-237.8	-39.8	386.1	196
Other Unusual Items	-15.5	-53.4	-	-	-	-
Pretax Income	5,145	4,780	4,199	4,859	9,326	3,810
Income Tax Expense	567.1	367.3	245.7	520.4	1,251	297.2
Net Income	4,578	4,413	3,954	4,338	8,075	3,513
Net Income to Common	4,578	4,413	3,954	4,338	8,075	3,513
Net Income Growth	-1.64%	11.61%	-8.87%	-46.28%	129.86%	66.05%
Shares Outstanding (Basic)	106	108	107	107	106	108
Shares Outstanding (Diluted)	110	115	114	114	112	115
Shares Change (YoY)	-4.39%	1.23%	0.18%	1.16%	-2.52%	0.44%
EPS (Basic)	43.30	40.90	37.05	40.51	76.40	32.65
EPS (Diluted)	41.59	38.34	34.77	38.22	71.97	30.52
EPS Growth	2.88%	10.27%	-9.03%	-46.89%	135.81%	65.33%
Free Cash Flow	4,222	3,665	3,875	4,425	6,529	2,004
Free Cash Flow Per Share	38.35	31.84	34.08	38.98	58.19	17.41
Gross Margin	45.83%	49.99%	52.32%	57.67%	67.04%	55.67%
Operating Margin	26.83%	29.19%	32.27%	41.03%	55.97%	43.13%
Profit Margin	32.13%	31.07%	30.14%	35.64%	50.24%	41.35%
Free Cash Flow Margin	29.63%	25.80%	29.54%	36.35%	40.63%	23.58%
EBITDA	4,348	4,628	4,654	5,335	9,281	3,901
EBITDA Margin	30.52%	32.59%	35.48%	43.83%	57.75%	45.90%
D&A For EBITDA	525.1	482.9	421	341.4	286.2	235.9
EBIT	3,823	4,145	4,233	4,994	8,995	3,665
EBIT Margin	26.83%	29.19%	32.27%	41.03%	55.97%	43.13%
Effective Tax Rate	11.02%	7.68%	5.85%	10.71%	13.41%	7.80%
Revenue as Reported	14,248	14,202	13,117	12,173	16,072	8,497

Updated Oct 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q